The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

@article{Rudick2002TheMS,
  title={The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials},
  author={Richard A. Rudick and Gary R. Cutter and Stephen C. Reingold},
  journal={Multiple Sclerosis},
  year={2002},
  volume={8},
  pages={359 - 365}
}
With the advent and widespread use of partially effective disease modifying drug therapies for multiple sclerosis (MS), future clinical trials will undoubtedly test experimental interventions against standard therapy, or will test combinations of drugs against standard therapy. In either case, incremental progress in slowing disability progression in future MS clinical trials will require much larger sample sizes, more sensitive outcome measures, or a combination of the two. Because improved… 
Possible clinical outcome measures for clinical trials in patients with multiple sclerosis
TLDR
A single clinical outcome measure of sustained disease progression may remain elusive and an integration of current and new outcome measures may be most appropriate and utilization of different measures depending on the MS population and stage of the disease may be preferred.
Functional clinical outcomes in multiple sclerosis: Current status and future prospects.
TLDR
Clinical data suggest that disease-modifying therapies may delay or prevent relapse, and better composite measures will be valuable in the assessment of disease activity-free status in people with MS.
Clinical outcome measures in multiple sclerosis: A review.
TLDR
The most frequently used COMs of MS progression are reviewed including their operationalization and statistical considerations, as well as newer composite COMs and digital tools on development.
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives
TLDR
The use of more refined outcomes and truly neuroprotective drugs, coupled with more efficient trial design, has the capacity to deliver a new era of therapeutic discovery in this challenging area.
Measuring Treatment Response in Progressive Multiple Sclerosis—Considerations for Adapting to an Era of Multiple Treatment Options
TLDR
Outcome measures and definitions of disease progression in phase III clinical trials in primary and secondary progressive multiple sclerosis are analyzed to discuss advantages and disadvantages of clinical and paraclinical outcome measures aiming for practical ways of combining them to detect disability progression more sensitively both in future clinical trials and current clinical routine.
Measuring Disability Progression with the Multiple Sclerosis Functional Composite
TLDR
A new approach to MSFC data involves defining MSFC progression as worsening in an MSFC component by 15–20% over three months, which could be used as a primary disability outcome in future clinical trials.
Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions
TLDR
This review will describe the most common treatment goals in MS: the Rio scores, disease-free survival, and no evidence of disease activity, and discuss future options for improving MS treatment targets.
Effect of drugs in secondary disease progression in patients with multiple sclerosis
TLDR
Investigation of the use of interferon beta for immunomodulation in patients with secondary progressive multiple sclerosis found it has the potential to significantly slow disease progression and improve quality of life for patients with SPMS.
Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis
TLDR
In trials involving patients with early stage RRMS and CIS, modifications to the FAMS based on a qualitative assessment of its content validity in these populations would be required in order to potentially improve the Fams psychometric properties and sensitivity.
Slowing the Progression of Multiple Sclerosis
TLDR
This chapter highlights key trials to point out results of historical significance and to relate interferon therapy to disease pathogenesis, and concludes with the hope that advances in understanding pathology and pathogenesis can lead to even more rapid progress over the next 20 years.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Development of a multiple sclerosis functional composite as a clinical trial outcome measure.
TLDR
A composite measure encompassing the major clinical dimensions of arm, leg and cognitive function was identified and termed the multiple sclerosis functional composite (MSFC), suggesting that the MSFC is more sensitive to change than the EDSS.
Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS
TLDR
MSFC scores in patients with RR-MS predict the level of disability and extent of brain atrophy 6 to 8 years later, and may prove useful to assign prognosis, monitor patients during early stages of MS, and to assess treatment effects.
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
TLDR
The MSFC demonstrated excellent intrarater reliability in this multinational phase 3 trial and the pattern of correlations among the MSFC, its components, and the Kurtzke Expanded Disability Status Scale supported the validity of the MS FC.
Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.
TLDR
This study supports a recommendation by the National Multiple Sclerosis Society Task Force to use the MSFC as a clinical outcome measure and observed strong correlations between MSFC scores and validated measures of self-reported quality of life indicate that the MS FC scores are clinically relevant.
Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
TLDR
This article provides recommendations from the National Multiple Sclerosis Society's Clinical Outcomes Assessment Task Force, which proposed a new measurement approach based on quantitative functional composites that consist of simple quantitative measures from the major clinical dimensions of MS combined into a single score.
Clinical outcomes assessment in multiple sclerosis
This article represents initial deliberation of an international task force appointed by the US National Multiple Sclerosis Society to develop recommendations for optimal clinical assessment tools
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis
TLDR
It was concluded that the formulation of a useful clinical trial design must be based on specific guidelines for clinical scales and imaging for which task forces were recommended and subsequently appointed.
MS Functional Composite
TLDR
The prospective study in subgroups of MS confirmed and extended the construct validity of the MSFC, which showed good concurrent validity with the EDSS, and includes information about cognition.
Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.
TLDR
Brain atrophy measurement and change in BPF was correlated with the changes in disability scores from the end of the phase III trial to the follow-up exam, suggesting that brain atrophy may be a useful and clinically relevant marker of disease progression in relapsing--remitting MS.
Concurrent validity of the MS Functional Composite using MRI as a biological disease marker
TLDR
The authors present the concurrent validity of the MSFC with a biological disease marker by showing correlations with MRI, which demonstrate significant correlations with cognition and arm/hand function assessments, domains that are not well represented in the EDSS.
...
1
2
3
...